ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 156 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $142,797 | -53.8% | 12,784 | -11.5% | 0.09% | -52.5% |
| Q2 2023 | $308,973 | +10.3% | 14,438 | +108.5% | 0.18% | +18.8% |
| Q1 2023 | $280,007 | -11.5% | 6,924 | +1.8% | 0.15% | -6.7% |
| Q4 2022 | $316,336 | +3.7% | 6,800 | +15.6% | 0.16% | +35.2% |
| Q3 2022 | $305,000 | +11.3% | 5,883 | +1.5% | 0.12% | +19.6% |
| Q2 2022 | $274,000 | -28.1% | 5,798 | +8.3% | 0.10% | -40.4% |
| Q1 2022 | $381,000 | -4.8% | 5,353 | 0.0% | 0.17% | +13.2% |
| Q4 2021 | $400,000 | -26.6% | 5,353 | -44.2% | 0.15% | -37.1% |
| Q3 2021 | $545,000 | +18.2% | 9,599 | -8.4% | 0.24% | +26.3% |
| Q2 2021 | $461,000 | -36.5% | 10,483 | -28.8% | 0.19% | -38.1% |
| Q1 2021 | $726,000 | +20.4% | 14,721 | +2.8% | 0.31% | +22.8% |
| Q4 2020 | $603,000 | +9.4% | 14,321 | +18.9% | 0.25% | -13.5% |
| Q3 2020 | $551,000 | -0.5% | 12,046 | +9.2% | 0.29% | +10.3% |
| Q2 2020 | $554,000 | +22.0% | 11,031 | +24.9% | 0.26% | +40.1% |
| Q1 2020 | $454,000 | -23.3% | 8,831 | -7.8% | 0.19% | +92.8% |
| Q4 2019 | $592,000 | +22.1% | 9,576 | +18.5% | 0.10% | -1.0% |
| Q3 2019 | $485,000 | -39.1% | 8,079 | -14.4% | 0.10% | -41.7% |
| Q2 2019 | $796,000 | -21.7% | 9,433 | -11.3% | 0.17% | -92.2% |
| Q1 2019 | $1,016,000 | +76.1% | 10,634 | +30.6% | 2.16% | +2083.8% |
| Q4 2018 | $577,000 | -4.3% | 8,140 | +15.4% | 0.10% | +59.7% |
| Q3 2018 | $603,000 | -20.9% | 7,052 | +7.2% | 0.06% | -90.8% |
| Q2 2018 | $762,000 | -39.7% | 6,577 | -57.9% | 0.67% | -38.5% |
| Q1 2018 | $1,263,000 | +22.7% | 15,613 | -10.9% | 1.10% | -15.1% |
| Q4 2017 | $1,029,000 | -31.8% | 17,531 | -45.6% | 1.29% | +536.0% |
| Q3 2017 | $1,509,000 | +30.1% | 32,235 | 0.0% | 0.20% | +17.3% |
| Q2 2017 | $1,160,000 | +15.8% | 32,235 | -0.9% | 0.17% | -2.8% |
| Q1 2017 | $1,002,000 | +1.7% | 32,521 | +10.6% | 0.18% | -39.5% |
| Q4 2016 | $985,000 | +38.9% | 29,394 | +10.3% | 0.29% | -14.3% |
| Q3 2016 | $709,000 | +37.9% | 26,649 | +14.4% | 0.34% | -10.0% |
| Q2 2016 | $514,000 | -6.4% | 23,292 | +24.6% | 0.38% | -49.6% |
| Q1 2016 | $549,000 | – | 18,689 | – | 0.76% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 476,042 | $45,472,000 | 12.29% |
| Stonepine Capital Management, LLC | 60,840 | $5,811,000 | 3.34% |
| ACUTA CAPITAL PARTNERS, LLC | 61,000 | $5,827,000 | 2.77% |
| Virtus ETF Advisers LLC | 10,634 | $1,016,000 | 2.16% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 61,000 | $5,827,000 | 2.15% |
| ARMISTICE CAPITAL, LLC | 372,000 | $35,533,000 | 1.94% |
| Matarin Capital Management, LLC | 209,403 | $20,002,000 | 1.46% |
| Monashee Investment Management LLC | 50,000 | $4,776,000 | 1.10% |
| Granahan Investment Management | 151,322 | $14,454,000 | 0.78% |
| ALGERT GLOBAL LLC | 13,186 | $1,260,000 | 0.72% |